HGS, BioInvent ink antibody deal

Human Genome Sciences and BioInvent International have inked a deal to discover, develop and commercialize therapeutic monoclonal antibodies that specifically target antigens discovered by HGS. BioInvent will use its antibody discovery technology to generate and develop monoclonal antibody candidates, with a focus on the field of inflammation. Financial terms were not disclosed. Release